JPWO2022240637A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022240637A5 JPWO2022240637A5 JP2023570121A JP2023570121A JPWO2022240637A5 JP WO2022240637 A5 JPWO2022240637 A5 JP WO2022240637A5 JP 2023570121 A JP2023570121 A JP 2023570121A JP 2023570121 A JP2023570121 A JP 2023570121A JP WO2022240637 A5 JPWO2022240637 A5 JP WO2022240637A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide complex
- group
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 67
- 229920001184 polypeptide Polymers 0.000 claims 57
- 102000004196 processed proteins & peptides Human genes 0.000 claims 57
- 150000001413 amino acids Chemical group 0.000 claims 29
- 229910052740 iodine Inorganic materials 0.000 claims 19
- 229910052720 vanadium Inorganic materials 0.000 claims 17
- 229910052731 fluorine Inorganic materials 0.000 claims 15
- 229910052698 phosphorus Inorganic materials 0.000 claims 15
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 229910052727 yttrium Inorganic materials 0.000 claims 10
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 108091005804 Peptidases Proteins 0.000 claims 6
- 239000004365 Protease Substances 0.000 claims 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 4
- 125000005647 linker group Chemical group 0.000 claims 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 3
- 239000000758 substrate Substances 0.000 claims 3
- 239000012636 effector Substances 0.000 claims 2
- 102000004580 Aspartic Acid Proteases Human genes 0.000 claims 1
- 108010017640 Aspartic Acid Proteases Proteins 0.000 claims 1
- 102000005927 Cysteine Proteases Human genes 0.000 claims 1
- 108010005843 Cysteine Proteases Proteins 0.000 claims 1
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 1
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 102000005741 Metalloproteases Human genes 0.000 claims 1
- 108010006035 Metalloproteases Proteins 0.000 claims 1
- 102000012479 Serine Proteases Human genes 0.000 claims 1
- 108010022999 Serine Proteases Proteins 0.000 claims 1
- 102000007562 Serum Albumin Human genes 0.000 claims 1
- 108010071390 Serum Albumin Proteins 0.000 claims 1
- 102000035100 Threonine proteases Human genes 0.000 claims 1
- 108091005501 Threonine proteases Proteins 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 229940116977 epidermal growth factor Drugs 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263327317P | 2020-04-04 | 2020-04-04 | |
| US202163187690P | 2021-05-12 | 2021-05-12 | |
| US63/187,690 | 2021-05-12 | ||
| US63/327,317 | 2022-04-04 | ||
| PCT/US2022/027688 WO2022240637A2 (en) | 2020-04-04 | 2022-05-04 | Compositions and methods related to tumor activated antibodies targeting egfr and effector cell antigens |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024518539A JP2024518539A (ja) | 2024-05-01 |
| JPWO2022240637A5 true JPWO2022240637A5 (https=) | 2025-05-08 |
| JP2024518539A5 JP2024518539A5 (https=) | 2025-05-08 |
Family
ID=84029363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023570121A Pending JP2024518539A (ja) | 2020-04-04 | 2022-05-04 | 抗体を標的とする腫瘍によって活性化されるｅｇｆｒおよびエフェクター細胞抗原に関する組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US12161724B2 (https=) |
| EP (1) | EP4337697A4 (https=) |
| JP (1) | JP2024518539A (https=) |
| KR (1) | KR20240035392A (https=) |
| CN (1) | CN117642156A (https=) |
| AR (1) | AR125758A1 (https=) |
| AU (1) | AU2022272906A1 (https=) |
| BR (1) | BR112023023650A2 (https=) |
| CA (1) | CA3218661A1 (https=) |
| MX (1) | MX2023013382A (https=) |
| TW (1) | TW202311289A (https=) |
| WO (1) | WO2022240637A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024518539A (ja) | 2020-04-04 | 2024-05-01 | ジャナックス セラピューティクス，インク． | 抗体を標的とする腫瘍によって活性化されるｅｇｆｒおよびエフェクター細胞抗原に関する組成物および方法 |
| EP4259177A4 (en) * | 2020-12-08 | 2024-11-06 | Janux Therapeutics, Inc. | Peptide compositions and methods for anti-cd3 binding domains |
| WO2025195305A1 (en) * | 2024-03-16 | 2025-09-25 | Vibrant Pharma Limited | Multispecific antigen binding proteins and uses thereof |
| WO2025201240A1 (en) * | 2024-03-25 | 2025-10-02 | Tavotek Biotherapeutics (Hong Kong) Limited | Antibodies targeting cd3, cd28, and pd-l1 and uses thereof |
| WO2025201560A1 (en) * | 2024-03-29 | 2025-10-02 | Vibrant Pharma Limited | Multispecific antigen-binding proteins and uses thereof |
| WO2026067689A1 (zh) * | 2024-09-28 | 2026-04-02 | 浙江道尔生物科技有限公司 | 肿瘤特异性激活的蛋白药物及其应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US7060808B1 (en) | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| CA2513113A1 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| TW201122101A (en) | 2009-10-28 | 2011-07-01 | Facet Biotech Corp | Anti-EGFR antibodies and their uses |
| WO2011123830A2 (en) | 2010-04-02 | 2011-10-06 | Amunix Operating Inc. | Alpha 1-antitrypsin compositions and methods of making and using same |
| EP2552967A4 (en) | 2010-04-02 | 2014-10-08 | Amunix Operating Inc | BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE |
| MX340556B (es) * | 2010-08-24 | 2016-07-14 | Roche Glycart Ag | Anticuerpos biespecificos activables. |
| CN103382223B (zh) | 2012-04-01 | 2015-06-10 | 上海益杰生物技术有限公司 | 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽 |
| SG10201608307WA (en) | 2012-04-20 | 2016-11-29 | Emergent Product Dev Seattle | Cd3 binding polypeptides |
| CN104540518A (zh) * | 2012-04-27 | 2015-04-22 | 西托姆克斯治疗公司 | 结合表皮生长因子受体的可活化的抗体其使用方法 |
| JP6092649B2 (ja) | 2013-02-15 | 2017-03-08 | キヤノン株式会社 | 演算装置、アレイ型演算装置およびその制御方法、情報処理システム |
| WO2015066279A2 (en) | 2013-10-30 | 2015-05-07 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| CN110627907B (zh) | 2013-11-04 | 2024-03-29 | 艾科诺斯科技股份有限公司 | 重靶向t细胞的异源二聚免疫球蛋白的产生 |
| BR112016015140A2 (pt) | 2013-12-30 | 2018-01-23 | Epimab Biotherapeutics Inc. | imunoglobulina com fabs in-tandem e usos das mesmas |
| JP7020909B2 (ja) | 2014-07-25 | 2022-02-16 | シトムクス セラピューティクス，インコーポレイティド | 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法 |
| US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
| CN105820248A (zh) | 2015-01-07 | 2016-08-03 | 上海张江生物技术有限公司 | 一种新型抗egfr单克隆抗体的制备方法及应用 |
| EA201792573A1 (ru) | 2015-05-21 | 2018-04-30 | Харпун Терапьютикс, Инк. | Триспецифические связанные белки и способы их применения |
| WO2017008169A1 (en) | 2015-07-15 | 2017-01-19 | Zymeworks Inc. | Drug-conjugated bi-specific antigen-binding constructs |
| US11649291B2 (en) | 2016-05-24 | 2023-05-16 | Insmed Incorporated | Antibodies and methods of making same |
| WO2019067015A1 (en) | 2017-09-29 | 2019-04-04 | City Of Hope | RECEPTORS OF CHIMERIC ANTIGENS AND BISPECIFIC ANTIBODIES FOR THE TREATMENT OF COAT CELL LYMPHOMA |
| CN114423499A (zh) * | 2019-06-06 | 2022-04-29 | 佳努克斯治疗公司 | 与肿瘤激活的t细胞衔接子相关的组合物和方法 |
| US20230121775A1 (en) | 2019-06-26 | 2023-04-20 | Amunix Pharmaceuticals, Inc. | Cd3 antigen binding fragments and compositions comprising same |
| CA3143522A1 (en) | 2019-06-26 | 2020-12-30 | Amunix Pharmaceuticals, Inc. | Egfr antigen binding fragments and compositions comprising same |
| KR20210043475A (ko) | 2019-10-10 | 2021-04-21 | 주식회사 와이바이오로직스 | 다중 특이적 융합 단백질 및 이의 용도 |
| JP2024518539A (ja) | 2020-04-04 | 2024-05-01 | ジャナックス セラピューティクス，インク． | 抗体を標的とする腫瘍によって活性化されるｅｇｆｒおよびエフェクター細胞抗原に関する組成物および方法 |
| WO2022035866A1 (en) | 2020-08-11 | 2022-02-17 | Janux Therapeutics, Inc. | Cleavable linker compositions and methods |
| WO2022094299A2 (en) | 2020-10-30 | 2022-05-05 | Janux Therapeutics, Inc. | Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof |
| EP4259177A4 (en) | 2020-12-08 | 2024-11-06 | Janux Therapeutics, Inc. | Peptide compositions and methods for anti-cd3 binding domains |
| EP4337794A4 (en) | 2021-05-11 | 2025-07-02 | Janux Therapeutics Inc | ANTIBODIES TARGETING EGFR AND CD3 AND THEIR USES |
| WO2024102723A2 (en) | 2022-11-10 | 2024-05-16 | Janux Therapeutics, Inc. | Antibodies targeting egfr and cd3 and uses thereof |
| EP4615879A2 (en) | 2022-11-11 | 2025-09-17 | Janux Therapeutics, Inc. | Compositions and uses of tumor activated antibodies targeting egfr and effector cell antigens |
-
2022
- 2022-05-04 JP JP2023570121A patent/JP2024518539A/ja active Pending
- 2022-05-04 TW TW111116883A patent/TW202311289A/zh unknown
- 2022-05-04 EP EP22808066.9A patent/EP4337697A4/en active Pending
- 2022-05-04 AU AU2022272906A patent/AU2022272906A1/en active Pending
- 2022-05-04 AR ARP220101168A patent/AR125758A1/es unknown
- 2022-05-04 KR KR1020237042777A patent/KR20240035392A/ko active Pending
- 2022-05-04 CA CA3218661A patent/CA3218661A1/en active Pending
- 2022-05-04 US US18/559,201 patent/US12161724B2/en active Active
- 2022-05-04 MX MX2023013382A patent/MX2023013382A/es unknown
- 2022-05-04 CN CN202280049696.XA patent/CN117642156A/zh active Pending
- 2022-05-04 BR BR112023023650A patent/BR112023023650A2/pt unknown
- 2022-05-04 WO PCT/US2022/027688 patent/WO2022240637A2/en not_active Ceased
-
2024
- 2024-10-17 US US18/919,094 patent/US12433953B2/en active Active
-
2025
- 2025-09-12 US US19/327,021 patent/US20260014267A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023052910A5 (https=) | ||
| CN113412281B (zh) | Btn3a结合蛋白及其用途 | |
| JP2021004250A (ja) | 改変した抗体組成物、それを作製および使用する方法 | |
| CN111315773A (zh) | 含有Fc区的条件性活化的结合部分 | |
| WO2022045247A1 (ja) | 抗切断型変異ｃａｌｒ－ｃｄ３二重特異性抗体及び医薬組成物 | |
| JPWO2020004492A5 (https=) | ||
| JP2020531430A (ja) | 抗体を標的とする抗ｃｔｌａ４プロボディ療法 | |
| JPWO2022174813A5 (https=) | ||
| JP2021506310A5 (https=) | ||
| JPH08501925A (ja) | 糖蛋白ｐに対するモノクローナル抗体 | |
| US20240019424A1 (en) | Method for resolving complex, multistep antibody interactions | |
| JPWO2022240637A5 (https=) | ||
| JP2008532559A5 (https=) | ||
| EP4592321A1 (en) | Anti-her2 antibodies and use thereof | |
| JPWO2022125576A5 (https=) | ||
| US20230227536A1 (en) | Immunogenicity-reduced low-molecular antibody and method for producing same | |
| JPWO2022183074A5 (https=) | ||
| CN118206654B (zh) | 用于疾病治疗的新型抗体及其产品和应用 | |
| JPWO2023141713A5 (https=) | ||
| HK40096312A (zh) | 用於解析复杂、多步骤抗体相互作用的方法 | |
| RU2026104696A (ru) | Антитела, связывающиеся с cd3 | |
| JPWO2020205875A5 (https=) | ||
| JPWO2023198635A5 (https=) | ||
| JPWO2022125566A5 (https=) | ||
| CN121758584A (zh) | Pth复合物及其应用 |